These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
32. Double-edged sword of the new cancer therapeutics. Force T Circulation; 2012 May; 125(17):2057-8. PubMed ID: 22451582 [No Abstract] [Full Text] [Related]
33. [Reversible pulmonary hypertension as a consequence of dasatinib treatment in a patient with chronic myeloid leukemia and scleroderma]. Ryczek R; Góra-Tybor J; Betkier-Lipińska K; Cwetsch A Pol Merkur Lekarski; 2013 Jun; 34(204):342-4. PubMed ID: 23882932 [TBL] [Abstract][Full Text] [Related]
34. Successful pregnancy involving a man with chronic myeloid leukemia on dasatinib. Oweini H; Otrock ZK; Mahfouz RA; Bazarbachi A Arch Gynecol Obstet; 2011 Jan; 283(1):133-4. PubMed ID: 20473616 [TBL] [Abstract][Full Text] [Related]
35. The efficacy of tolvaptan in treating dasatinib-induced pleural effusions in patients with chronic myelogenous leukemia. Aoyama R; Ishikawa J; Harada K J Cardiol; 2020 Feb; 75(2):203-207. PubMed ID: 31416783 [TBL] [Abstract][Full Text] [Related]
37. Change of right ventricular systolic pressure can indicate dasatinib-induced pulmonary arterial hypertension in chronic myeloid leukemia. Lee SE; Hyun Kong J; Kim SH; Jang EJ; Chung NG; Cho B; Joong Oh S; Jung HE; Youn HJ; Chung WB; Kim DW Cancer Med; 2021 Mar; 10(5):1515-1524. PubMed ID: 33590711 [TBL] [Abstract][Full Text] [Related]
39. [Repeated partially reversible pulmonary arterial hypertension related to dasatinib: a case report and literature review]. Jin J; Xu XM; Wang C Zhonghua Jie He He Hu Xi Za Zhi; 2016 Feb; 39(2):83-7. PubMed ID: 26879609 [TBL] [Abstract][Full Text] [Related]
40. New drugs: paliperidone, dasatinib, and decitabine. Hussar DA J Am Pharm Assoc (2003); 2007; 47(2):298-302. PubMed ID: 17510013 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]